Zapanta Rinonos, Serendipity http://orcid.org/0000-0001-9712-5747
Li, Tie
Pianka, Sean Thomas http://orcid.org/0000-0002-8924-5762
Prins, Terry J. http://orcid.org/0000-0003-4680-1359
Eldred, Blaine S. C. http://orcid.org/0000-0002-3351-3895
Kevan, Bryan M.
Liau, Linda M. http://orcid.org/0000-0002-4053-0052
Nghiemphu, Phioanh Leia http://orcid.org/0000-0003-4064-6079
Cloughesy, Timothy F. http://orcid.org/0000-0002-8656-7483
Lai, Albert http://orcid.org/0000-0002-7265-2986
Funding for this research was provided by:
UCLA Jonsson Comprehensive Cancer Center Postdoctoral Research Award (2021FP04)
UCLA Tumor Biology Postdoctoral Training Program (T32 CA009056)
UCLA Tumor Cell Biology Predoctoral Training Program (T32 CA009056)
National Cancer Institute Ruth L. Kirschstein Research Service Award (F30CA247525-01A1)
UCLA-Caltech Medical Scientist Training Program (NIGMS T32 GM008042)
U.S. Department of Defense (CA190604)
BCured Foundation (20199389)
UCLA SPORE in Brain Cancer (NCI P50 CA211015)
Article History
Received: 9 October 2023
Accepted: 4 December 2023
First Online: 15 January 2024
Declarations
:
: SZR, TL, STP, and AL have a U.S. Provisional Patent Application No. 63/429348 entitled TARGETED EPIGENETIC EDITING AS NOVEL THERAPY FOR MALIGNANT GLIOMA, filed on 12/1/2022. Official patent filing is currently in process, as of the time of manuscript submission. TJP, BSCE and BMK declare no potential conflicts of interest. LML is a board member and stock holder of ClearPoint Neuro, on the medical advisory board of InSightec, a paid consultant for ImmPact Bio, and has received research funding through UCLA from Northwest Biotherapeutics. PLN has contracts with UCLA for the Brain Tumor Program with BMS, Chimerix, Erasca, Springsworks, and Recursion. TFC is cofounder, major stock holder, consultant and board member of Katmai Pharmaceuticals, member of the board and paid consultant for the 501c3 Global Coalition for Adaptive Research, holds stock in Chimerix and receives milestone payments and possible future royalties, member of the scientific advisory board for Break Through Cancer, member of the scientific advisory board for Cure Brain Cancer Foundation, has provided paid consulting services to Sagimet, Clinical Care Options, Ideology Health, Servier, Jubilant, Immvira, Gan & Lee, BrainStorm, Katmai, Sapience, Inovio, Vigeo Therapeutics, DNATrix, Tyme, SDP, Novartis, Roche, Kintara, Bayer, Merck, Boehinger Ingelheim, VBL, Amgen, Kiyatec, Odonate Therapeutics QED, Medefield, Pascal Biosciences, Bayer, Tocagen, Karyopharm, GW Pharma, Abbvie, VBI, Deciphera, VBL, Agios, Genocea, Celgene, Puma, Lilly, BMS, Cortice, Wellcome Trust, Novocure, Novogen, Boston Biomedical, Sunovion, Human Longevity, Insys, ProNai, Pfizer, Notable labs, Medqia Trizel, Medscape and has contracts with UCLA for the Brain Tumor Program with Oncovir, Merck, Oncoceutics, Novartis, Amgen, Abbvie, DNAtrix, Beigene, BMS, AstraZeneca, Kazia, Agios, Boston Biomedical, Deciphera, Tocagen, Orbus, AstraZeneca, Karyopharm. The Regents of the University of California (TFC employer) has licensed intellectual property co-invented by TFC to Katmai Pharmaceuticals.